Jefferies downgraded Astria Therapeutics (ATXS) to Hold from Buy with a price target of $13, down from $30, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm expects the deal to close on time in Q1 of 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS: